Methadone containing products used for opioid use disorder (Q20-20)
Q20-20
Overview
Background
- Methadone is used for the treatment of opioid use disorder.
- In 2014/2015, most Canadian public drug plans transitioned from the existing 1mg/ml pharmacist-compounded formulation to Methadone 10 mg/ml, a more stable pre-mixed formulation. Subsequent to this policy change, there has been reports that some patients may experience decreased effectiveness with the newer methadone formulation.
- There is a need to better understand whether switching from one methadone-containing to another is associated with changes in measures of drug effectiveness or safety.
Aims of the study
- The study objective is to determine the proportion of patients who experience safety outcomes when switching from compounded methadone, Methadose or Metadol-D to another formulation or brand, and the short-term outcomes in these patients.